Sheena Jonathan, the co-founder and director of Natera, Inc. (NASDAQ:NTRA), has sold a significant portion of her holdings in the company. According to a recent filing, Jonathan sold shares totaling approximately $5.62 million. The sales occurred on November 13, 2024, with transaction prices ranging from $152.6878 to $160.0204 per share.
Following these transactions, Jonathan holds 259,772 shares directly. Additionally, shares are held indirectly by trusts, including Caraluna 1 Trust and Caraluna 2 Trust, for the benefit of their beneficiaries. The sales were conducted under a pre-arranged trading plan, ensuring compliance with regulatory requirements.
In other recent news, Natera Inc (NASDAQ:NTRA). has reported significant financial growth, revealing a 64% year-over-year increase in sales, gross margins surpassing consensus estimates, and a strong free cash flow of $35 million for the quarter. This performance has led to a revision of the company's full-year revenue guidance to between $1.61 billion and $1.64 billion. In response to these results, analyst firms TD Cowen, Baird, and Jefferies have all maintained positive ratings on Natera's stock and increased their price targets.
The company's sales growth was partly driven by a 71% increase in sales of Signatera, Natera's cancer detection test, and contributions from the Women's Health segment. The company's oncology test volumes saw a significant increase, with 137,000 tests performed, a 54% increase from the previous year.
Amid these developments, Natera continues to see significant growth opportunities ahead with over 100 trials underway. However, the company noted challenges with private payers and potential holiday-related disruptions in the fourth quarter. Despite these challenges, the company's strong performance and positive outlook have been recognized by analyst firms, emphasizing Natera's recent successes and future potential.
InvestingPro Insights
Natera, Inc. (NASDAQ:NTRA) has been experiencing significant market momentum, as evidenced by the recent insider sale and several key financial indicators. According to InvestingPro data, Natera's stock has shown impressive returns, with a 176.58% price total return over the past year and a substantial 133.17% year-to-date return. This strong performance aligns with the timing of Sheena Jonathan's decision to sell shares, potentially capitalizing on the stock's upward trajectory.
The company's revenue growth has been robust, with a 54.94% increase in the last twelve months as of Q3 2024, reaching $1.53 billion. This growth trend is further supported by an InvestingPro Tip indicating that 6 analysts have revised their earnings upwards for the upcoming period, suggesting positive expectations for Natera's financial performance.
Despite the strong market performance, it's worth noting that Natera operates with a negative P/E ratio of -89.82, reflecting that the company is not currently profitable. This is corroborated by another InvestingPro Tip stating that analysts do not anticipate the company will be profitable this year. However, with liquid assets exceeding short-term obligations and a moderate level of debt, Natera appears to be in a stable financial position to continue its growth trajectory.
For investors seeking a more comprehensive analysis, InvestingPro offers 14 additional tips for Natera, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.